Kintai Therapeutics, a Flagship Pioneering company, today announced the advancement of KTX-0200, a novel oral anti-obesity agent, into IND-enabling studies following the demonstration of sustained weight loss and improved markers of health in preclinical studies. Treatment […]
Human microbiome research is one of the most relevant fields of innovation based on the large range of applications known and sectors currently or potentially involved. In fact, the US therapeutics market is meant to […]
Bloom Science, a biopharmaceutical company focused on the discovery and development of precision living medicines for currently untreatable neurological diseases, today announced signing of an agreement with Duke University, granting the Company an option to […]
Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN), announced today that it has entered a service agreement with Biose Industrie, a France based CDMO, for […]
Mawi DNA Technologies, a biotechnology company focusing on the development of innovative technologies for biosampling, announces a collaboration with CosmosID to help advance understanding of microbiome complexity in different biological samples and environments. “Our fellow […]
Bayer and Azitra Inc., a clinical-stage medical dermatology biotech company, today announced a joint development agreement to collaborate in the identification and characterization of skin microbiome bacteria. The partnership will leverage Azitra’s proprietary panel of […]
Locus Biosciences announced today that it has opened for enrollment a Phase 1b clinical trial evaluating LBP-EC01, a CRISPR Cas3-enhanced bacteriophage (crPhage™) product that will target Escherichia coli (E. coli) bacteria causing urinary tract infections […]
Finch Therapeutics Group, Inc. (“Finch”), a clinical-stage microbiome therapeutics company, announced today that it has completed enrollment in PRISM3, its multi-center, placebo-controlled Phase 2 clinical trial evaluating CP101. CP101 is an oral, potentially first-in-class microbiome […]
Jennewein Biotechnology announces another milestone in the worldwide approval of a new product generation, the “HMO-Mix.” The data of the toxicological study, with the title “A Safety Evaluation of Mixed Human Milk Oligosaccharides in Rats,” […]
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces the opening of a clinical study to evaluate the safety and preliminary clinical efficacy of MRx0518 in combination with […]
On January 2nd, the Psomagen–Macrogen Consortium announced the acquisition of all key assets of US company uBiome. Through the move, Psomagen has become a key player in the microbiome sector, a promising next-generation bio healthcare […]